July 9 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Wednesday that its experimental drug to treat a type of obesity met the main goal in a mid-stage study.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.